The novel coronavirus has killed more than 100,000 people in the United States, according to a Reuters tally, even as the slowdown in deaths encouraged businesses to reopen and Americans to emerge from more than two months of lockdowns.
Global coronavirus cases surpassed 5 million, with Latin America overtaking the United States and Europe in the past week to report the largest portion of new daily cases globally.
AstraZeneca reported plans to manufacture as much as 30 million doses of the University of Oxford’s COVID-19 vaccine for the U.K. market by September 2020, with expectations of 100 million doses by the end of the year.
Businesses, professional bodies and individual practitioners have to keep talking at a time like this, not least because patients’ non-Covid-related needs have not disappeared overnight. How are lines of communication holding up, and what might this tell us about life after Covid-19?
The United Kingdom’s COVID-19 death toll exceeds 40,000, by far the worst yet reported in Europe, raising more questions about Prime Minister Boris Johnson’s handling of the coronavirus crisis.
A brief roundup of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.
Scientists at Britain’s Oxford University started a clinical trial to investigate the effects of an HIV medicine and a steroid drug in UK patients admitted to hospital with COVID-19 caused by the new coronavirus.
As part of strategic refocusing, AstraZeneca sold the rights to two cancer drugs in several countries in Europe, Africa and other countries to Juvisé Pharmaceuticals.
Vertex Pharmaceuticals Inc. priced the company’s FDA-approved Trikafta, a three-drug combination for cystic fibrosis, at $311,503 per year.
Indianapolis-based Eli Lilly announced the closing of the company’s Surrey, U.K.-based Erl Wood neuroscience research center by the end of 2020, affecting 270 staffers.
